Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;4(4):101676.
doi: 10.1016/j.jacadv.2025.101676. Epub 2025 Mar 22.

Primary Prevention of Cardiovascular Disease in Asia: Opportunities and Solutions: A Narrative Review

Mayank Dalakoti  1 , Norman H Y Lin  2 , Jonathan Yap  3 , Aaysha Cader  4 , Prajapati Dipanker  5 , Derek Lee  6 , Raja Ezman Raja Shariff  7 , Lucky Cuenza  8 , Satoshi Honda  9 , Vorn Malis  10 , Haowen Jiang  11 , Anish Hirachan  12 , Misato Chimura  13 , Tee Joo Yeo  2 , Khung Keong Yeo  3 , Tan Jack Wei Chieh  14 , Jasper Tromp  15 , Poay Huan Loh  2 , Nicholas W S Chew  16 , Scott Wong  2 , Ching-Hui Sia  16 , Benjamin Y Q Tan  17 , Sofian Johar  18 , Gregory Y H Lip  19 , Eugene Yang  20 , Salim S Virani  21 , Steven Hageman  22 , Hueiming Liu  23 , Emanuele Di Angelantonio  24 , Prabhakaran Dorairaj  25 , Angela S Koh  26 , Calvin Chin  26 , Wael Al Mahmeed  27 , Mark Y Chan  16 , Roger Foo  16
Affiliations

Primary Prevention of Cardiovascular Disease in Asia: Opportunities and Solutions: A Narrative Review

Mayank Dalakoti et al. JACC Adv. 2025 Apr.

Abstract

Importance: Asia faces a rapidly rising burden of cardiovascular disease (CVD). Preventive cardiology efforts may help address the CVD epidemic.

Observations: Solutions to address the CVD burden include a cardiovascular risk assessment framework, improving health screening efforts, better cardiovascular risk factor management, novel innovation strategies encompassing targeted lifestyle measures, and strengthening governmental efforts. With the region's wide socioeconomic and other disparities, contextualizing and practical adaptation of various strategies into local practices, especially in low-middle-income countries, will determine the success of CVD prevention efforts.

Conclusions: A differential approach addressing cardiovascular risk factor screening, prevention, and management that considers the context-specific socioeconomic, governmental, and cultural aspects in diverse Asian populations may help reduce the rapidly rising CVD trajectory in Asia.

Keywords: cardiovascular disease prevention in Asia; opportunities and solutions; primary prevention.

PubMed Disclaimer

Conflict of interest statement

Funding support and author disclosures This research is supported by the Singapore Ministry of Health's National Medical Research Council under its National Medical Research Council (“NMRC”) Open Fund—Large Collaborative Grant (“OF-LCG”) (OFLCG22may-0010), Project RESET: Redirecting immune, lipid, and metabolic drivers of early cardiovascular disease. Dr Tromp is supported by the National University of Singapore Start-up grant, the tier 1 grant from the ministry of education and the CS-IRG New Investigator Grant from the National Medical Research Council; has received consulting or speaker fees from Daiichi Sankyo, Boehringer Ingelheim, Roche Diagnostics, and Us2.ai, owns patent US-10702247-B2 unrelated to the present work. Dr Yap has received speaker honorarium from Abbott, Biosensors, Biotronik, Boston Scientific, Edwards, GE HealthCare, J&J, Kaneka, Medtronic, and Terumo. Dr Raja Shariff has received speaker honorarium from AstraZeneca, Novartis, Boehringer Ingelheim, and General Electric. Dr Yeo has received research funding from Amgen, AstraZeneca, Abbott Vascular, Bayer, Boston Scientific, Shockwave Medical, Novartis; has received consulting fees from Abbott Vascular, Medtronic, Novartis, and Peijia Medical; has received speaker fees from Shockwave Medical, Abbott Vascular, Boston Scientific, Medtronic, Alvimedica, Biotronik, OrbusNeich, Shockwave Medical, Amgen, Novartis, AstraZeneca, Microport, Terumo, and Omnicare; is also cofounder and owns equity in Trisail for which OrbusNeich is an investor. Dr Chan has received research grants from AstraZeneca, Eli Lilly, Bayer, the National Medical Research Council, Singapore, and National Research Foundation, Singapore. Dr Chimura has received research grants and personal fees from Otsuka Pharma, Daiwa Foundation, and the Japan Research Foundation for Clinical Pharmacology. Dr Virani has received research support from NIH, NIHR USA, Department of Veterans Affairs USA, Tahir and Jooma Family and Asharia Family. Dr Koh has received research support from National Medical Research Council, Singapore, Edwards Lifesciences, and Abbott. Dr Yang has served on the advisory board of Idorsia, Mineralys, Qure.ai, and Sky Labs; has consulting for Genentech; has received honoraria from American College of Cardiology; and has received research grants from Microsoft Research. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
Central Illustration
Central Illustration
Challenges in Cardiovascular Disease in Asia CVD = cardiovascular disease.
Figure 1
Figure 1
Implementation Cycle of Preventive Cardiology Strategies
Figure 2
Figure 2
Examples of 6P Toolkit
See this image and copyright information in PMC

References

    1. Asian economic integration report 2022. 2022. https://aric.adb.org/pdf/aeir/AEIR2022_5_movement-of-people.pdf
    1. Zhao D. Epidemiological features of cardiovascular disease in Asia. JACC Asia. 2021;1(1):1–13. doi: 10.1016/j.jacasi.2021.04.007. - DOI - PMC - PubMed
    1. The cost of silence: cardiovascular disease in Asia. An Economist Intelligence Unit Report. 2018. https://impact.economist.com/perspectives/sites/default/files/The_cost_o...
    1. Yusuf P.S., Hawken S., Ôunpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. doi: 10.1016/S0140-6736(04)17018-9. - DOI - PubMed
    1. Wilson P.W.F., D’Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847. doi: 10.1161/01.CIR.97.18.1837. - DOI - PubMed

LinkOut - more resources